tbuckley/cabot-search huggingface dataset:
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
Authors: Meenakshi Hegde, Shoba Navai, Christopher DeRenzo, Sujith K. Joseph, Khaled Sanber, Mengfen Wu, Ahmed Z. Gad, Katherine A. Janeway, Matthew Campbell, Dolores Mullikin, Zeid Nawas, Catherine Robertson, Pretty R. Mathew, Huimin Zhang, Birju Mehta, Raksha R. Bhat, Angela Major, Ankita Shree, Claudia Gerken, Mamta Kalra, Rikhia Chakraborty, Sachin G. Thakkar, Olga Dakhova, Vita S. Salsman, Bambi Grilley, Natalia Lapteva, Adrian Gee, Gianpietro Dotti, Riyue Bao, Ahmed Hamed Salem, Tao Wang, Malcolm K. Brenner, Helen E. Heslop, Winfried S. Wels, M. John Hicks, Stephen Gottschalk, Nabil Ahmed
Journal: Nature Cancer (2024)
JAK-STAT signaling maintains homeostasis in T cells and macrophages
Authors: Nikolaus Fortelny, Matthias Farlik, Victoria Fife, Anna-Dorothea Gorki, Caroline Lassnig, Barbara Maurer, Katrin Meissl, Marlies Dolezal, Laura Boccuni, Aarathy Ravi Sundar Jose Geetha, Mojoyinola Joanna Akagha, Anzhelika Karjalainen, Stephen Shoebridge, Asma Farhat, Ulrike Mann, Rohit Jain, Shweta Tikoo, Nina Zila, Wolfgang Esser-Skala, Thomas Krausgruber, Katarzyna Sitnik, Thomas Penz, Anastasiya Hladik, Tobias Suske, Sophie Zahalka, Martin Senekowitsch, Daniele Barreca, Florian Halbritter, Sabine Macho-Maschler, Wolfgang Weninger, Heidi A Neubauer, Richard Moriggl, Sylvia Knapp, Veronika Sexl, Birgit Strobl, Thomas Decker, Mathias Müller, Christoph Bock
Journal: Nature Immunology (2024)

Abstract Immune cells need to sustain a state of constant alertness over a lifetime. Yet, little is known about the regulatory processes that control the fluent and fragile balance that is called homeostasis. Here we demonstrate that JAK-STAT signaling, beyond its role in immune responses, is a major regulator of immune cell homeostasis. We investigated JAK-STAT-mediated transcription and chromatin accessibility across 12 mouse models, including knockouts of all STAT transcription factors and of the TYK2 kinase. Baseline JAK-STAT signaling was detected in CD8 + T cells and macrophages of unperturbed mice—but abrogated in the knockouts and in unstimulated immune cells deprived of their normal tissue context. We observed diverse gene-regulatory programs, including effects of STAT2 and IRF9 that were independent of STAT1. In summary, our large-scale dataset and integrative analysis of JAK-STAT mutant and wild-type mice uncovered a crucial role of JAK-STAT signaling in unstimulated immune cells, where it contributes to a poised epigenetic and transcriptional state and helps prepare these cells for rapid response to immune stimuli.
Joint genotypic and phenotypic outcome modeling improves base editing variant effect quantification
Authors: Jayoung Ryu, Sam Barkal, Tian Yu, Martin Jankowiak, Yunzhuo Zhou, Matthew Francoeur, Quang Vinh Phan, Zhijian Li, Manuel Tognon, Lara Brown, Michael I. Love, Vineel Bhat, Guillaume Lettre, David B. Ascher, Christopher A. Cassa, Richard I. Sherwood, Luca Pinello
Journal: Nature Genetics (2024)
Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT)
Authors: Oliver Carlile, Andrew Briggs, Alasdair D. Henderson, Ben F.C. Butler-Cole, John Tazare, Laurie A. Tomlinson, Michael Marks, Mark Jit, Liang-Yu Lin, Chris Bates, John Parry, Sebastian C.J. Bacon, Iain Dillingham, William A. Dennison, Ruth E. Costello, Alex J. Walker, William Hulme, Ben Goldacre, Amir Mehrkar, Brian MacKenna, Alex Walker, Amelia Green, Amir Mehrkar, Andrea Schaffer, Andrew Brown, Ben Goldacre, Ben Butler-Cole, Brian MacKenna, Caroline Morton, Caroline Walters, Catherine Stables, Christine Cunningham, Christopher Wood, Colm Andrews, David Evans, George Hickman, Helen Curtis, Henry Drysdale, Iain Dillingham, Jessica Morley, Jon Massey, Linda Nab, Lisa Hopcroft, Louis Fisher, Lucy Bridges, Milan Wiedemann, Nicholas DeVito, Orla Macdonald, Peter Inglesby, Rebecca Smith, Richard Croker, Robin Park, Rose Higgins, Sebastian Bacon, Simon Davy, Steven Maude, Thomas O'Dwyer, Tom Ward, Victoria Speed, William Hulme, Liam Hart, Pete Stokes, Krishnan Bhaskaran, Ruth Costello, Thomas Cowling, Ian Douglas, Rosalind Eggo, Stephen Evans, Harriet Forbes, Richard Grieve, Daniel Grint, Emily Herrett, Sinead Langan, Viyaasan Mahalingasivam, Kathryn Mansfield, Rohini Mathur, Helen McDonald, Edward Parker, Christopher Rentsch, Anna Schultze, Liam Smeeth, John Tazare, Laurie Tomlinson, Jemma Walker, Elizabeth Williamson, Kevin Wing, Angel Wong, Bang Zheng, Christopher Bates, Jonathan Cockburn, John Parry, Frank Hester, Sam Harper, Shaun O'Hanlon, Alex Eavis, Richard Jarvis, Dima Avramov, Paul Griffiths, Aaron Fowles, Nasreen Parkes, Rafael Perera, David Harrison, Kamlesh Khunti, Jonathan Sterne, Jennifer Quint, Emily Herrett, Rosalind M. Eggo
Journal: The Lancet Regional Health - Europe (2024)
Refined risk stratification helps guiding transplantation choice in adult BCR::ABL1-positive acute lymphoblastic leukemia
Authors: Cheng Wang, Jianfeng Li, Weiyang Liu, Lingling Zhao, Han Yan, Yuchen Yan, Jiayi Ren, Lijun Peng, Jiaojiao Zhang, Yuanfang Liu, Xiangqin Weng, Yongmei Zhu, Duohui Jing, Jian-Qing Mi, Jin Wang
Journal: Blood Cancer Journal (2024)
Suppression of Hb Bart's to improve tissue oxygenation and fetal development in homozygous alpha‐thalassemia
Authors: G. Lugthart, E. J. T. Verweij, C. L. Harteveld, R. N. G. B. Tan, M. F. C. M. Knapen, F. Slaghekke, M. C. Haak, A. B. Mohseny, F. J. Smiers
Journal: American Journal of Hematology (2024)

Intra-uterine reduction of Hb Bart's only reached with exchange transfusions.
Contribution of VEGF-B-Induced Endocardial Endothelial Cell Lineage in Physiological Versus Pathological Cardiac Hypertrophy
Authors: Ibrahim Sultan, Markus Ramste, Pim Peletier, Karthik Amudhala Hemanthakumar, Deepak Ramanujam, Annakaisa Tirronen, Ylva von Wright, Salli Antila, Pipsa Saharinen, Lauri Eklund, Eero Mervaala, Seppo Ylä-Herttuala, Stefan Engelhardt, Riikka Kivelä, Kari Alitalo
Journal: Circulation Research (2024)

Preclinical studies have shown the therapeutic potential of VEGF-B (vascular endothelial growth factor B) in revascularization of the ischemic myocardium, but the associated cardiac hypertrophy and adverse side effects remain a concern. To understand the importance of endothelial proliferation and migration for the beneficial versus adverse effects of VEGF-B in the heart, we explored the cardiac effects of autocrine versus paracrine VEGF-B expression in transgenic and gene-transduced mice.
<scp>GLP</scp>‐1 agonists and <scp>SGLT</scp>‐2 inhibitors in adults with sickle cell disease
Authors: Ryan Sun, Anand Srivastava, Vimal K. Derebail, Jin Han, Robert E. Molokie, Victor Gordeuk, Santosh L. Saraf
Journal: American Journal of Hematology (2024)
Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer
Authors: Yufan Ying, Yuqing Wu, Fenghao Zhang, Yijie Tang, Jiahe Yi, Xueyou Ma, Jiangfeng Li, Danni Chen, Xiao Wang, Xiaoyan Liu, Ben Liu, Jindan Luo, Xiangyi Zheng, Liping Xie
Journal: Molecular Cancer (2024)

R-loops are prevalent three-stranded nucleic acid structures, comprising a DNA-RNA hybrid and a displaced single-stranded DNA, that frequently form during transcription and may be attributed to genomic stability and gene expression regulation. It was recently discovered that RNA modification contributes to maintain the stability of R-loops such as N6-methyladenosine (m
Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor <scp>AML</scp> patients in <scp>CR2</scp>: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Authors: Yishan Ye, Myriam Labopin, Socié Gérard, Ibrahim Yakoub‐Agha, Igor Wolfgang Blau, Mahmoud Aljurf, Edouard Forcade, Tobias Gedde‐Dahl, David Burns, Jan Vydra, Khalid Halahleh, Rose‐Marie Hamladji, Ali Bazarbachi, Arnon Nagler, Eolia Brissot, Lin Li, Yi Luo, Yanmin Zhao, Fabio Ciceri, He Huang, Mohamad Mohty, Norbert Claude Gorin
Journal: American Journal of Hematology (2024)

Abstract Allogeneic hematopoietic cell transplantation (allo‐HCT) is recommended for core‐binding factor mutated (CBF) AML patients achieving second complete remission (CR2). However, approximately 20% of patients may relapse after transplant and donor preference remains unclear. We compared in this EBMT global multicenter registry‐based analysis the allo‐HCT outcomes using either haploidentical (Haplo), matched siblings donors (MSD), or 10/10 matched unrelated donors (MUD). Data from 865 de novo adult CBF AML patients in CR2 receiving allo‐HCT in 227 EBMT centers from 2010 to 2022 were analyzed, in which 329 MSD, 374 MUD, and 162 Haplo‐HCTs were included. For the entire cohort, 503 (58%) patients were inv(16)/CBFB‐MYH11 and 362 patients (42%) were t (8;21)/RUNX1‐RUNX1T1 AML. On multivariate analysis, Haplo‐HCT was associated with a lower Relapse Incidence (RI) compared to either MSD (hazard ratio [HR] = 0.56, 95% CI 0.32–0.97; p &lt; .05) or MUD (HR = 0.57, 95% CI: 0.33–0.99, p &lt; .05). No significant difference was observed among the 3 types of donors on LFS, OS and GRFS. CBF‐AML with t (8;21) was associated with both higher RI (HR = 1.79, 95% CI 1.3–2.47; p &lt; .01) and higher NRM (HR = 1.58, 95% CI 1.1–2.27; p &lt; .01) than CBF‐AML with inv(16), which led to worse LFS, OS and GRFS. To conclude, for CBF‐AML patients in CR2, Haplo‐HCTs were associated with a lower RI compared to MSD and MUD allo‐HCTs. There was no difference on LFS, OS or GRFS. CBF AML patients with inv(16) had a better progonosis than those with t (8;21) after allo‐HCT in CR2.
Temporal variations in the serogroup distribution of invasive meningococcal disease in Quebec, Canada, due to emerging unique clade of serogroup Y strain belonging to the Sequence Type-23 clonal complex
Authors: Raymond S.W. Tsang, Genevieve Deceuninck, Courtney Meilleur, Jianwei Zhou, Brigitte Lefebvre, Philippe De Wals
Journal: Journal of Infection (2024)

To identify recent trends in invasive meningococcal diseases (IMD) in Quebec, Canada, with a focus on MenY cases and MenY strains.
Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage–tumor interaction axes among different lineages of pituitary neuroendocrine tumors
Authors: Shaojian Lin, Yuting Dai, Changxi Han, Tianyi Han, Linfeng Zhao, Renyan Wu, Jianyue Liu, Bo Zhang, Ning Huang, Yanting Liu, Shujing Lai, Jintong Shi, Yu Wang, Meiqing Lou, Jing Xie, Yijun Cheng, Hao Tang, Hong Yao, Hai Fang, Yan Zhang, Xuefeng Wu, Lei Shen, Youqiong Ye, Li Xue, Zhe Bao Wu
Journal: Genome Medicine (2024)

Pituitary neuroendocrine tumors (PitNETs) are common gland neoplasms demonstrating distinctive transcription factors. Although the role of immune cells in PitNETs has been widely recognized, the precise immunological environment and its control over tumor cells are poorly understood. The heterogeneity, spatial distribution, and clinical significance of macrophages in PitNETs were analyzed using single-cell RNA sequencing (scRNA-seq), bulk RNA-seq, spatial transcriptomics, immunohistochemistry, and multiplexed quantitative immunofluorescence (QIF). Cell viability, cell apoptosis assays, and in vivo subcutaneous xenograft experiments have confirmed that INHBA-ACVR1B influences the process of tumor cell apoptosis. The present study evaluated scRNA-seq data from 23 PitNET samples categorized into 3 primary lineages. The objective was to explore the diversity of tumors and the composition of immune cells across these lineages. Analyzed data from scRNA-seq and 365 bulk RNA sequencing samples conducted in-house revealed the presence of three unique subtypes of tumor immune microenvironment (TIME) in PitNETs. These subtypes were characterized by varying levels of immune infiltration, ranging from low to intermediate to high. In addition, the NR5A1 lineage is primarily associated with the subtype characterized by limited infiltration of immune cells. Tumor-associated macrophages (TAMs) expressing CX3CR1+, C1Q+, and GPNMB+ showed enhanced contact with tumor cells expressing NR5A1 + , TBX19+, and POU1F1+, respectively. This emphasizes the distinct interaction axes between TAMs and tumor cells based on their lineage. Moreover, the connection between CX3CR1+ macrophages and tumor cells via INHBA-ACVR1B regulates tumor cell apoptosis. In summary, the different subtypes of TIME and the interaction between TAM and tumor cells offer valuable insights into the control of TIME that affects the development of PitNET. These findings can be utilized as prospective targets for therapeutic interventions.
A biomimetic spore nanoplatform for boosting chemodynamic therapy and bacteria-mediated antitumor immunity for synergistic cancer treatment
Authors: Cuixia Zheng, Lingling Sun, Hongjuan Zhao, Mengya Niu, Dandan Zhang, Xinxin Liu, Qingling Song, Weijie Zhong, Baojin Wang, Yun Zhang, Lei Wang
Journal: Asian Journal of Pharmaceutical Sciences (2024)

Bacterial-based antitumor immunity has become a promising strategy to activate the immune system for fighting cancer. However, the potential application of bacterial therapy is hindered by the presence of instability and susceptibility to infections within bacterial populations. Furthermore, monotherapy is ineffective in completely eliminating complex cancer with multiple contributing factors. In this study, based on our discovery that spore shell (SS) of
Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.12.015
Authors: Geoffrey H. Rosen, Nicholas H. Chakiryan, Katie S. Murray
Journal: European Urology (2024)
Sirt6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma
Authors: Fan Xia, Shuizhen Shi, Erick Palacios, Wei Liu, Seth E Buscho, Joseph Li, Shixia Huang, Gianmarco Vizzeri, Xiaocheng Charlie Dong, Massoud Motamedi, Wenbo Zhang, Hua Liu
Journal: Molecular Therapy (2024)

Glaucoma is characterized by the progressive degeneration of retinal ganglion cells (RGCs) and their axons, and its risk increases with aging. Yet comprehensive insights into the complex mechanisms are largely unknown. Here, we found that anti-aging molecule Sirt6 was highly expressed in RGCs. Deleting Sirt6 globally or specifically in RGCs led to progressive RGC loss and optic nerve degeneration during aging, despite normal intraocular pressure (IOP), resembling a phenotype of normal-tension glaucoma. These detrimental effects were potentially mediated by accelerated RGC senescence through Caveolin-1 upregulation and by the induction of mitochondrial dysfunction. In mouse models of high-tension glaucoma, Sirt6 level was decreased after IOP elevation. Genetic overexpression of Sirt6 globally or specifically in RGCs significantly attenuated high tension-induced degeneration of RGCs and their axons, whereas partial or RGC-specific Sirt6 deletion accelerated RGC loss. Importantly, therapeutically targeting Sirt6 with pharmacological activator or AAV2-mediated gene delivery ameliorated high IOP-induced RGC degeneration. Together, our studies reveal a critical role of Sirt6 in preventing RGC and optic nerve degeneration during aging and glaucoma, setting the stage for further exploration of Sirt6 activation as a potential therapy for glaucoma.
Controlling CAR-T cell activity and specificity with synthetic SparX adapters
Authors: Justin P Edwards, Jeffrey S Swers, Janine M Buonato, Liubov Zaritskaya, C Jenny Mu, Ankit Gupta, Sigal Shachar, David W LaFleur, Laura K Richman, David A Tice, David M Hilbert
Journal: Molecular Therapy (2024)

While conventional chimeric antigen-receptor (CAR)-T therapies have shown remarkable clinical activity in some settings, they can induce severe toxicities and are rarely curative. To address these challenges, we developed a controllable cell therapy where synthetic D-domain-containing proteins (soluble protein antigen-receptor X-linker [SparX]) bind one or more tumor antigens and mark those cells for elimination by genetically modified T cells (antigen-receptor complex [ARC]-T). The chimeric antigen receptor was engineered with a D-domain that specifically binds to the SparX protein via a unique TAG, derived from human alpha-fetoprotein. The interaction is mediated through an epitope on the TAG that is occluded in the native alpha-fetoprotein molecule. In vitro and in vivo data demonstrate that the activation and cytolytic activity of ARC-T cells is dependent on the dose of SparX protein and only occurs when ARC-T cells are engaged with SparX proteins bound to antigen-positive cells. ARC-T cell specificity was also redirected in vivo by changing SparX proteins that recognized different tumor antigens to combat inherent or acquired tumor heterogeneity. The ARC-SparX platform is designed to expand patient and physician access to cell therapy by controlling potential toxicities through SparX dosing regimens and enhancing tumor elimination through sequential or simultaneous administration of SparX proteins engineered to bind different tumor antigens.
Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study
Authors: Yalei Zhang, Ling Qian, Kun Chen, Sijia Gu, Zhiqiang Meng, Jia Wang, Ye Li, Peng Wang
Journal: Molecular Therapy (2024)

Malignant ascites is a common complication resulting from the peritoneal spread of malignancies, and currently lacks effective treatments. We conducted a phase II trial (NCT04771676) to investigate the efficacy and safety of oncolytic adenovirus H101 and virotherapy-induced immune response in 25 patients with malignant ascites. Oncolytic virotherapy achieved an increased median time to repeat paracentesis of 45 days (95% confidence interval 16.5-73.5 days), compared with the preset control value of 13 days. Therapy was well-tolerated, with pyrexia, fatigue, nausea, and abdominal pain as the most common toxicities. Longitudinal single-cell profiling identified marked oncolysis, early virus replication, and enhanced CD8+ T cells-macrophages immune checkpoint crosstalk, especially in responsive patients. H101 also triggered a proliferative burst of CXCR6+ and GZMK+CD8+ T cells with promoted tumor-specific cytotoxicity. Further establishment of oncolytic virus-induced T cell expansion signature (OiTE) implicated the potential benefits for H101-responsive patients from subsequent anti-PD(L)1 therapy. Patients with upregulated immune-signaling pathways in tumor cells and a higher proportion of CLEC10A+ dendritic cells and GZMK+CD8+ T cells at baseline showed a superior response to H101 treatment. Our study demonstrates promising clinical responses and tolerability of oncolytic adenovirus in treating malignant ascites and provides insights into the relevant cellular processes following oncolytic virotherapy.
Beyond dopamine: Novel strategies for schizophrenia treatment
Authors: Paulina Dudzik, Klaudia Lustyk, Karolina Pytka
Journal: Medicinal Research Reviews (2024)

Despite extensive research efforts aimed at discovering novel antipsychotic compounds, a satisfactory pharmacological strategy for schizophrenia treatment remains elusive. All the currently available drugs act by modulating dopaminergic neurotransmission, leading to insufficient management of the negative and cognitive symptoms of the disorder. Due to these challenges, several attempts have been made to design agents with innovative, non-dopaminergic mechanisms of action. Consequently, a number of promising compounds are currently progressing through phases 2 and 3 of clinical trials. This review aims to examine the rationale behind the most promising of these strategies while simultaneously providing a comprehensive survey of study results. We describe the versatility behind the cholinergic neurotransmission modulation through the activation of M
Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer’s disease
Authors: Lina Vandermeulen, Ivana Geric, Laura Fumagalli, Mohamed Kreir, Ashley Lu, Annelies Nonneman, Jessie Premereur, Leen Wolfs, Rafaela Policarpo, Nicola Fattorelli, An De Bondt, Ilse Van Den Wyngaert, Bob Asselbergh, Mark Fiers, Bart De Strooper, Constantin d’Ydewalle, Renzo Mancuso
Journal: Molecular Neurodegeneration (2024)

Abstract Background Microglia play important roles in maintaining brain homeostasis and neurodegeneration. The discovery of genetic variants in genes predominately or exclusively expressed in myeloid cells, such as Apolipoprotein E ( APOE ) and triggering receptor expressed on myeloid cells 2 ( TREM2 ), as the strongest risk factors for Alzheimer’s disease (AD) highlights the importance of microglial biology in the brain. The sequence, structure and function of several microglial proteins are poorly conserved across species, which has hampered the development of strategies aiming to modulate the expression of specific microglial genes. One way to target APOE and TREM2 is to modulate their expression using antisense oligonucleotides (ASOs). Methods In this study, we identified, produced, and tested novel, selective and potent ASOs for human APOE and TREM2 . We used a combination of in vitro iPSC-microglia models, as well as microglial xenotransplanted mice to provide proof of activity in human microglial in vivo. Results We proved their efficacy in human iPSC microglia in vitro, as well as their pharmacological activity in vivo in a xenografted microglia model. We demonstrate ASOs targeting human microglia can modify their transcriptional profile and their response to amyloid-β plaques in vivo in a model of AD. Conclusions This study is the first proof-of-concept that human microglial can be modulated using ASOs in a dose-dependent manner to manipulate microglia phenotypes and response to neurodegeneration in vivo .
Randomized investigation of the <scp>MitraClip</scp> device in heart failure: Design and rationale of the <scp>RESHAPE‐HF2</scp> trial design
Authors: Stefan D. Anker, Tim Friede, Ralph Stephan von Bardeleben, Javed Butler, Kaneez Fatima, Monika Diek, Jutta Heinrich, Gerd Hasenfuß, Wolfgang Schillinger, Piotr Ponikowski
Journal: European Journal of Heart Failure (2024)

The safety and effectiveness of the MitraClip device to treat functional mitral regurgitation (FMR) has been tested in previous clinical trials yielding somewhat heterogeneous results in heart failure (HF) patients. Over time, the MitraClip device system has been modified and clinical practice evolved to consider also less severely diseased HF patients with FMR for this therapeutic option. The RESHAPE-HF2 trial aims to assess the safety and effectiveness of the MitraClip device system on top of medical therapy considered optimal in the treatment of clinically significant FMR in symptomatic patients with chronic HF.
Lung ultrasound for diagnosis and management of ARDS
Authors: Marry R. Smit, Paul H. Mayo, Silvia Mongodi
Journal: Intensive Care Medicine (2024)

Lung ultrasonography (LUS) is invaluable for diagnosing and managing adult respiratory distress syndrome (ARDS) because it is non-invasive, bedside, and widely available in both high-and low-resource settings.This article summarizes the technique and utility of LUS in ARDS patients.